Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

60.0%

3 terminated/withdrawn out of 5 trials

Success Rate

25.0%

-61.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

400%

4 of 1 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 3

3(75.0%)

Phase 2

1(25.0%)

4Total

Phase 3(3)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT05208866Phase 3Terminated

Roll-over Study to Assess Safety of Lixivaptan in Participants With ADPKD Who Completed Study PA-ADPKD-303

Role: lead

NCT04152837Phase 3Terminated

Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease

Role: lead

NCT04064346Phase 3Terminated

Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease

Role: lead

NCT03487913Phase 2Completed

The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease

Role: lead

NCT03717181Unknown

Lixivaptan in a Single Subject With Intractable Pain Due to Polycystic Kidney Disease

Role: lead

All 5 trials loaded